David Shaw’s BridgeBio Pharma BBIO Stock Holding History

David Shaw’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.3M	Buy	+30,900	New	+$2.16M	﹤0.01%	3080

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

David Shaw's BBIO Position: Q2 2026 in Review

David Shaw increased its BridgeBio Pharma (BBIO) stake by 43% in Q2 2026, buying an estimated $76.2M and bringing the position to 3,633,007 shares worth $271M. The position accounts for 0.13% of the portfolio, ranked #155.

David Shaw first reported a position in BBIO in Q1 2020 and has held it in 22 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

David Shaw held 3,633,007 shares of BridgeBio Pharma worth $271M as of Q2 2026.
David Shaw bought 1,087,521 BridgeBio Pharma shares in Q2 2026, an estimated $76.2M.
BridgeBio Pharma made up 0.13% of David Shaw's portfolio in Q2 2026, its #155 holding.
David Shaw first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 22 quarters since.
471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.